Compare Acetylon Pharmaceuticals vs Prolexys Pharmaceuticals
Customers evaluate the quality of Acetylon Pharmaceuticals's products using the following success metrics.
Overview
Acetylon Pharmaceuticals is based in United States
Acetylon Pharmaceuticals is a provider in the development of small molecule drugs targeting epigenetic mechanisms for the enhancement of therapeutic outcomes in cancer and other critical human diseases. The Company's epigenetic drug discovery platform has yielded a portfolio of optimized, orally-administered Class I and Class II histone deacetylase (HDAC) selective compounds. Alteration of HDAC regulation through selective HDAC inhibition is thought to be applicable to a broad range of diseases including cancer, sickle cell disease and beta-thalassemia, and autoimmune and neurodegenerative diseases. Acetylon's lead drug candidate, ACY-1215, is a selective HDAC6 inhibitor currently in Phase 1b clinical development for the treatment of multiple myeloma.
Prolexys Pharmaceuticals is 23 yrs old and is based in United States.
Prolexys Pharmaceuticals is a developer of cancer and cardiovascular small molecule drugs.
Demo Video
Leadership
Kenneth C Anderson (Founder)
David L Clark (Chief Executive Officer)
Funding
Investors
Celgene, Leukemia & Lymphoma Society
Friedli Corporate Finance and New Venturetec
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Acetylon Pharmaceuticals has not claimed their profile.
Work for Acetylon Pharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Acetylon Pharmaceuticals?
Claim your profile now.
Information not available because Prolexys Pharmaceuticals has not claimed their profile.
Work for Prolexys Pharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Prolexys Pharmaceuticals?
Claim your profile now.